We cloned the novel inhibitory receptor B and T Lymphocyte Attenuator (BTLA) in a previous cycle of this Program Project grant, and established that it is an important general regulator of immune responses. By generating and examining BTLA knockout mice, we found that BTLA regulates immune responses in several model systems, including several models of autoimmunity. We also recognized and described polymorphisms in BTLA in the mouse that influence its expression and distribution. Importantly, polymorphisms of BTLA in humans were recently linked to susceptibility to Rheumatoid arthritis, highlighting the importance of fully understanding the mechanism of BTLA action. Regulation of the intensity and the duration of immune responses is a critical for balancing the protective responses against pathogens with damage to tissues that are their result. Inhibitory receptors such as CTLA- 4, PD-1 and BTLA can contribute to this balance by ensuring that appropriate thresholds exist for activating the immune response, and by limiting the intensity and duration of responses that are initiated. However, there are still many basic issues about BTLA that are unresolved. Recent findings by our lab have identified a wholly unexpected and unprecedented interaction between BTLA, a member of the CD28/B7 Ig super family of receptors, with Herpesvirus entry mediator (HVEM), a TNF receptor family member. Our identification of HVEM as the BTLA ligand arose as part of our previous Aims to clone the ligand for BTLA, and this finding has now been confirmed by others. It is important to note that the binding between BTLA and HVEM occurs in the mouse and the human systems. While BTLA may be inhibitory, HVEM can provide activating, pro-survival signals. In fact, our recent findings and preliminary data indicate evidence for a bi- directional signaling, which has potential for delivering both inhibitory and pro-survival signals. Thus, the current application is aimed at dissecting both directions of the BTLA-HVEM interaction so that its contribution to human autoimmunity such as Rheumatoid arthritis can be understood at the basic level.
Our aims are:
Aim 1. Discriminate cell-intrinsic from cell-extrinsic actions of BTLA in distinct models of immune response and autoimmunity.
Aim 2. Analyze the cytoplasmic signaling motifs in BTLA.
Aim 3. Determine the bidirectional interactions between BTLA, LIGHT, and HVEM for signaling. Project Narrative: Autoimmunity is a major problem of health and human disease, which result from various modes of failure of the tolerance mechanisms of the immune system. Autoimmune diseases have many kinds of manifestations, such as immune responses that target the joints (arthritis), the endocrine cells of the pancreas (diabetes) or the filtering mechanism of the kidney (Lupus). Our study is directed at analyzing the basic mechanisms that control the normal activation and inhibition of the immune response, and are focused on a new gene, B and T Lymphocyte Attenuator (BTLA), that we discovered and cloned as a part of previous cycles of this same grant. Importantly, BTLA has recently been reported to be involved in the susceptibility in humans to rheumatoid arthritis. Thus, our proposed studies into this newly identified but poorly understood molecule are particularly timely.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI076427-02
Application #
7860295
Study Section
Cellular and Molecular Immunology - B Study Section (CMIB)
Program Officer
Peyman, John A
Project Start
2009-06-05
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2012-05-31
Support Year
2
Fiscal Year
2010
Total Cost
$345,541
Indirect Cost
Name
Washington University
Department
Pathology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Anderson 3rd, David A; Murphy, Kenneth M; Briseño, Carlos G (2018) Development, Diversity, and Function of Dendritic Cells in Mouse and Human. Cold Spring Harb Perspect Biol 10:
Anderson 3rd, David A; Grajales-Reyes, Gary E; Satpathy, Ansuman T et al. (2017) Revisiting the specificity of the MHC class?II transactivator CIITA in classical murine dendritic cells in vivo. Eur J Immunol 47:1317-1323
Haldar, Malay; Kohyama, Masako; So, Alex Yick-Lun et al. (2014) Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages. Cell 156:1223-1234
Satpathy, Ansuman T; Briseño, Carlos G; Lee, Jacob S et al. (2013) Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol 14:937-48
Wu, Xiaodi; Satpathy, Ansuman T; Kc, Wumesh et al. (2013) Bcl11a controls Flt3 expression in early hematopoietic progenitors and is required for pDC development in vivo. PLoS One 8:e64800
Satpathy, Ansuman T; Wu, Xiaodi; Albring, Jorn C et al. (2012) Re(de)fining the dendritic cell lineage. Nat Immunol 13:1145-54
Tussiwand, Roxane; Lee, Wan-Ling; Murphy, Theresa L et al. (2012) Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490:502-7
Satpathy, Ansuman T; KC, Wumesh; Albring, Jörn C et al. (2012) Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J Exp Med 209:1135-52
Ise, Wataru; Kohyama, Masako; Schraml, Barbara U et al. (2011) The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol 12:536-43
Albring, Jörn C; Sandau, Michelle M; Rapaport, Aaron S et al. (2010) Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med 207:2551-9

Showing the most recent 10 out of 11 publications